

Depression of the Intestinal Uptake of Radio-vitamin B₁₂ by Cholestyramine¹ (37237)

ANDREW CORONATO² AND GEORGE B. JERZY GLASS

*Section of Gastroenterology and Gastroenterology Research Laboratory, Department of Medicine,
New York Medical College, New York, New York 10029*

Since cholic acid depresses the intestinal uptake of radio-vitamin B₁₂ *in vivo* and *in vitro* (1), it seemed reasonable to explore the effect of sequestering bile acids with cholestyramine (CH) on the absorption of radio-vitamin B₁₂ in man.

Methods. *In vivo*, the double label hepatic uptake (DLHU) test (2) was used to quantitatively measure the absorption of radio-vitamin B₁₂. Following an overnight fast, background counts were taken over the liver for both ⁵⁷Co-B₁₂ and ⁶⁰Co-B₁₂. Individuals were then given 1.0 μg of ⁶⁰Co-B₁₂ (0.51 μCi/μg) orally and 0.05 μg of ⁵⁷Co-B₁₂ (10 μCi/μg) intravenously. Fourteen days later, counting for both cobalt isotopes was repeated over the liver and the percentage absorption was calculated as previously described (2). The reproducibility of the DLHU test was previously demonstrated by performing the test twice at 2 wk intervals in five consecutive individuals (1).

The effect of CH on vitamin B₁₂ absorption was studied in 10 normal volunteers. In the first six volunteers, control B₁₂ absorption without CH was performed first. They were then given 4 g of CH orally four times a day for four consecutive days and the radio-B₁₂ was administered on Day 3. In the last four patients, the sequence was reversed such that CH was given first and control absorption was performed 14 days later.

In vitro, the guinea pig intestinal mucosal homogenate (GPIMH) assay described by Castro-Curel and Glass (3) was used. Gas-

tric juice (GJ) was collected from a normal volunteer by performing a maximal histamine stimulation test. The 30 and 60 min specimens were pooled, brought to pH 10 with 1.0 M NaOH, and then to pH 7.0 with 1.0 M HCl. The neutralized GJ was then strained through gauze, divided into 2 ml aliquots and frozen. Each assay was performed in duplicate in the following manner. To a 15 ml test tube containing 5 ml of Krebs-Henseleit bicarbonate glucose medium, the following were added: (a) 1 ml ⁵⁷Co-B₁₂ containing 2500 pg vitamin B₁₂, the specific activity of which provided 4-6 cpm/pg; (b) 1 ml suspension of GPIMH in normal saline containing 12 mg GPIMH; (c) 0.025 ml of gastric juice (GJ) diluted to 1.0 ml with normal saline; and (d) 1 ml of a suspension of CH at a concentration of 15 mg/ml. In order to study the possible effect of CH on the various phases of the intrinsic factor (IF)-mediated uptake of B₁₂ by the GPIMH, the reagents were mixed in different sequences:

1. B₁₂ + GPIMH;
2. B₁₂ + GJ + GPIMH;
3. B₁₂ + GJ + CH + GPIMH;
4. B₁₂ + CH + GJ + GPIMH;
5. CH + GJ + B₁₂ + GPIMH;
6. GPIMH + CH + GJ + B₁₂.

The mixtures were incubated at 5° for 1 hr as described by England, Ashworth and Taylor (4) rather than at 37°. This was found to lower the non-IF-mediated uptake, but had no effect on the IF-mediated uptake thereby increasing the difference between the two 7- to 10-fold as opposed to incubating at 37° which showed a difference of 2- to 3-fold.

In order to further study the effect of CH

¹ This work was supported by the Training Grant in Gastroenterology No. TI-AM-5237 and Research Grant No. AM-00068-21 of the NIAMD, NIH, PHS.

² U.S. Public Health Service Trainee in Gastroenterology.




FIG. 1. The effect of cholestyramine on radio-B₁₂ absorption in normal adult volunteers as measured by the double label hepatic uptake test.

on the IF activity of GJ, 1 ml dilutions of GJ containing 0.025 ml of GJ were extracted with increasing amounts of CH (1, 10, 30, and 66 mg). The extractions were performed by shaking the GJ and CH thoroughly, centrifuging and using only the supernatant GJ in the subsequent assays.

Results. *In vivo*, CH was found to lower the absorption of radio-B₁₂ in all 10 volunteers as shown in Fig. 1. The mean absorption of the controls was $88 \pm 18.9\%$, while that of the individuals treated with CH was $54 \pm 7.6\%$. This difference was significant by the *t* test applied to paired comparisons, with the $p < 0.01$. CH administration also diminished the absorption of radio-B₁₂ in a patient with pernicious anemia (Fig. 2). When B₁₂ was given together with IF, CH decreased the percentage absorption from 50 to 34%. When B₁₂ was given without IF, CH decreased the percentage absorption from 21 to 15%, values well within the limits of reproducibility.

In vitro studies performed by means of the GPIMH assay were done to explore the mechanism of CH depression of B₁₂ absorption. In the GPIMH system, CH produced a marked reduction in radio-B₁₂ uptake when allowed to react with GJ prior to the addition of radio-B₁₂ [Fig. 3, sequences 5, 6 (see Method)]. This did not occur when CH was added after B₁₂ and GJ had been previously

mixed (Fig. 3, sequence 3), or if CH was allowed to react with B₁₂ prior to the addition of GJ (Fig. 3, sequence 4).

Since this suggested that CH decreases the radio-B₁₂ uptake by binding a portion of the IF in GJ and thereby preventing the formation of the IF-B₁₂ complex, we attempted to decrease the IF activity of GJ by previously extracting it with CH.

GJ was extracted with CH as previously described. The extracted GJ showed an asymptotic decrease in IF activity as it was extracted with increasing amounts of CH (Fig. 4).

Discussion. The results of this study indi-




FIG. 2. The effect of cholestyramine on the intestinal absorption of radio-B₁₂ in a pernicious anemia patient as measured by the double label hepatic uptake test.




FIG. 3. The effect of cholestyramine on the IF-mediated uptake of ⁵⁷Co-B₁₂ by GPIMH.

cate that CH decreases the intestinal absorption of radio-B₁₂ in normal volunteers and in a patient with pernicious anemia. The mechanism of this inhibition was explored *in vitro* using the GPIMH assay. The results of the *in vitro* studies suggest that CH decreases the uptake of radio-B₁₂ probably by binding a portion of the same binding sites on the IF molecule which normally bind vitamin B₁₂ and thereby preventing the formation of the IF-B₁₂ complex. There was no evidence to suggest that this inhibition occurred as a result of CH binding free vitamin B₁₂, the IF-B₁₂ complex, or receptor sites on the ileal

mucosa. It had previously been shown that cholic acid and possibly deoxycholic acid decreased the absorption of radio-B₁₂, while glycocholic acid and glycodeoxycholic acid had no effect on radio-B₁₂ absorption (1). It seemed unlikely then, that the CH decrease in radio-B₁₂ absorption was mediated via the sequestration of bile acids.

Cholestyramine is a basic anion exchange resin with a strong affinity for binding bile acids in the intestinal tract and thereby decreasing their absorption (5). A number of other agents including warfarin, phenylbutazone, chlorothiazide, and phenobarbital can be bound by cholestyramine *in vitro* and their absorption can be delayed *in vivo* when they are administered simultaneously with a single dose of cholestyramine (6). Bergman, Heedman and Van der Linden (7) found that cholestyramine impaired the absorption of orally administered thyroxine in Syrian hamsters and inhibited the transport of thyroxine across the wall of isolated rat intestinal sacs. It also significantly decreased the absorption of thyroxine in patients receiving both drugs, and caused the clinical relapse of the patient's hypothyroid state (8). Thomas, McCullough and Greenberger (9), demonstrated that CH could bind both inorganic and organic iron *in vitro* and could significantly impair the absorption of both in rats.




FIG. 4. Uptake of ⁵⁷Co-B₁₂ by GPIMH after cholestyramine extraction of gastric juice.

The question of whether long-term treatment with CH can deplete vitamin B₁₂ stores and lead to megaloblastic anemia cannot be answered at this time. One can speculate, however, that it seems unlikely that decreasing an individual's normal absorption of vitamin B₁₂ from 90 to 55% would deplete his vitamin B₁₂ stores. However, if an individual with previously borderline vitamin B₁₂ absorptive capacity (*e.g.*, patients with subtotal gastrectomy, atrophic gastritis, or inflammatory disease of the small bowel) were placed on long-term CH therapy, it is reasonable to assume that this individual's stores would eventually be depleted and macrocytic anemia could develop.

Summary. Cholestyramine decreased the intestinal absorption of radio-B₁₂ as measured by the double label hepatic uptake test in 10 consecutive normal adult volunteers, and in a patient with pernicious anemia. The mechanism of this inhibition was explored *in vitro* using the guinea pig intestinal mucosal homogenate assay. The *in vitro* studies suggested that cholestyramine decreased intrinsic factor-mediated B₁₂ absorp-

tion probably by binding to a portion of the same binding sites on the intrinsic factor molecule which normally bind B₁₂. This would impair the formation of the intrinsic factor-B₁₂ complex.

1. Coronato, A., and Glass, G. B. J., Proc. Soc. Exp. Biol. Med. **142**, 1345 (1973).
2. Weisberg, H., and Glass, G. B. J., J. Lab. Clin. Med. **68**, 163 (1966).
3. Castro-Curel, Z., and Glass, G. B. J., Proc. Soc. Exp. Biol. Med. **112**, 715 (1963).
4. England, J. M., Ashworth, L. A. E., and Taylor, K. B., Quart. J. Exp. Physiol. **52**, 357 (1967).
5. Dalta, D. V., and Sherlock, S., Brit. Med. J. **1**, 216 (1963).
6. Gallo, D. G., Bailey, K. R., and Sheffner, A. L., Proc. Soc. Exp. Biol. Med. **120**, 60 (1965).
7. Bergman, F., Heedman, P. A., and Van der Linden, W., Acta. Endocrinol. **53**, 256 (1966).
8. Northcutt, R. C., Stiel, J. N., Hollifield, J. W., and Stant, E. G., J. Amer. Med. Ass. **208**, 1857 (1969).
9. Thomas, F. B., McCullough, F. S., and Greenberger, N. J., J. Lab. Clin. Med. **78**, 70 (1971).

Received Dec. 14, 1972. P.S.E.B.M., 1973, Vol. 142.